Education
About Us
Working with TipRanks
Follow Us
Pharmaxis Ltd (AU:SNT)
ASX:SNT
SNT Stock Chart & Stats
AU$0.03
>-AU$0.01(-6.33%)
At close: 4:00 PM EST
AU$0.03
>-AU$0.01(-6.33%)
Day’s Range― - ―
52-Week RangeAU$0.02 - AU$0.10
Previous CloseN/A
Volume5.35M
Average Volume (3M)3.71M
Market Cap
AU$50.60M
Enterprise ValueAU$71.13M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta3.02
Next Earnings
Feb 06, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding1,632,399,200
10 Day Avg. Volume2,483,870
30 Day Avg. Volume3,709,067
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$0.13Price Target Upside333.33% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Syntara Limited News
SNT FAQ
What was Pharmaxis Ltd’s price range in the past 12 months?
Pharmaxis Ltd lowest share price was AU$0.02 and its highest was AU$0.10 in the past 12 months.
What is Pharmaxis Ltd’s market cap?
Pharmaxis Ltd’s market cap is AU$50.60M.
When is Pharmaxis Ltd’s upcoming earnings report date?
Pharmaxis Ltd’s upcoming earnings report date is Feb 06, 2026 which is in 53 days.
How were Pharmaxis Ltd’s earnings last quarter?
Pharmaxis Ltd released its earnings results on Aug 28, 2025. The company reported -AU$0.003 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.003.
Is Pharmaxis Ltd overvalued?
According to Wall Street analysts Pharmaxis Ltd’s price is currently Undervalued.
Does Pharmaxis Ltd pay dividends?
Pharmaxis Ltd does not currently pay dividends.
What is Pharmaxis Ltd’s EPS estimate?
Pharmaxis Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Pharmaxis Ltd have?
Pharmaxis Ltd has 1,632,399,200 shares outstanding.
What happened to Pharmaxis Ltd’s price movement after its last earnings report?
Pharmaxis Ltd reported an EPS of -AU$0.003 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Pharmaxis Ltd?
Currently, no hedge funds are holding shares in AU:SNT
Syntara Limited Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
AU$0.13 (333.33% Upside)
AU$0.13 (333.33% Upside)
Blogger Sentiment
Bullish
AU:SNT Sentiment 94%
Sector Average ―
Sector Average ―
Technicals
SMA
Negative
20 days / 200 days
Momentum
-34.04%
12-Months-Change
Fundamentals
Return on Equity
-118.44%
Trailing 12-Months
Asset Growth
106.56%
Trailing 12-Months
Company Description
Pharmaxis Ltd
Pharmaxis Ltd is an Australia based pharmaceutical research company engaged in the research, development, and commercialization of human healthcare products for the treatment and management of fibrotic and inflammatory diseases. The firm's research efforts are focused on discovering drugs to treat inflammatory and fibrotic diseases such as NASH, pulmonary fibrosis, kidney and liver fibrosis and cancer from its amine oxidase inhibitor chemistry platform. Its product pipeline also includes Orbital and ASM8. The operating segments are Mannitol respiratory business and New Drug Development. It generates maximum revenue from Mannitol respiratory business segment.
SNT Stock 12 Month Forecast
Average Price Target
AU$0.13
▲(333.33% Upside)
Technical Analysis
Alterity Therapeutics
―
Genetic Signatures Ltd.
―
Radiopharm Theranostics Limited
―
Recce Pharmaceuticals Ltd.
―
PainChek Ltd
―
Options Prices
Currently, No data available
---